EXEL Reports STELLAR-303 Results
Exelixis reports final STELLAR-303 analysis showing non-significant OS trend favoring zanzalintinib and Tecentriq combo in non-liver metastases mCRC
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.